Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2023-05-19 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement from the board of directors of 马应龙药业集团股份有限公司 regarding the revision of the company's Articles of Association (公司章程). It details changes to the company's business scope and states that the changes will be submitted to the shareholders' meeting for approval. The document is relatively short (1656 characters) and does not contain financial data, audit information, or detailed reports. It is a formal announcement about governance-related changes, specifically the amendment of the company's charter. Therefore, it fits best under Governance Information (CGR).
2023-05-19 Chinese
马应龙公司章程（2023年修订）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Articles of Association" or "Company Bylaws". It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, share issuance, shareholder meetings, voting procedures, and other governance-related rules. The content is legal and regulatory in nature, focusing on the internal rules and governance framework of the company rather than financial performance, audit results, or meeting announcements. It is a comprehensive governance document, not an announcement or a report of financial results or voting outcomes. Therefore, the document fits best under the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2023-05-19 Chinese
马应龙独立董事关于提名非独立董事候选人的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the nomination of a non-independent director candidate for the company's board. It references compliance with company bylaws and regulatory rules but does not contain financial data or report on financial performance. It is related to board/management information, specifically about board nominations. The document length is short and focused on governance matters, not a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG).
2023-05-19 Chinese
马应龙关于召开2022年度暨2023年第一季度业绩说明会的公告
Call Transcript Classification · 95% confidence The document is an announcement about the scheduling of a performance explanation meeting (业绩说明会) for the 2022 annual results and 2023 first quarter results. It provides details on the meeting time, location, format (video and online interaction), and how investors can participate and ask questions. It references that the 2022 annual report and 2023 Q1 report have already been published on earlier dates. The document does not contain actual financial data or detailed financial statements but serves to inform investors about the upcoming earnings call or performance explanation meeting. This matches the definition of a Call Transcript (CT) type document, which includes full text transcripts or announcements of company conference calls or earnings calls with Q&A. Given the document length is short and it is an announcement of the meeting rather than the transcript itself, it is best classified as a Call Transcript (CT) announcement type rather than an Annual Report or Interim Report. Confidence is high due to clear references to the earnings explanation meeting and investor Q&A format.
2023-05-16 Chinese
马应龙2023年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年第一季度报告" which translates to "2023 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The report explicitly states it is unaudited and covers the quarterly period ending March 31, 2023. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2023
2023-04-28 Chinese
马应龙关于控股股东部分股份解除质押及再质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and re-pledged, along with the dates and parties involved. There is no financial statement, earnings data, or management discussion. The document is a formal disclosure about share pledging activities, which relates to capital structure but is not a financing update per se. It is not a report or a presentation but a regulatory announcement about share pledging. This fits best under Regulatory Filings (RNS) as it is a compliance disclosure about share pledge status and does not fit other more specific categories like Capital/Financing Update (CAP) which usually involves new financing or capital raising activities.
2023-04-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.